J Rosenstock, DR Hassman, RD Madder, SA … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Enrolled patients (n = 150) had received treatment with diet and
exercise in the previous 3 months with HbA 1c >7 and ≤12%. Patients were randomized to receive
monotherapy with repaglinide (n = ... Cited by 63 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org J Gerich, P Raskin, L Jean-Louis, D Purkayastha, … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—We conducted a randomized, multicenter, double-masked, 2-year study of
428 drug-naïve patients with type 2 diabetes. Patients received 120 mg ac nateglinide or 1.25 mg qd
glyburide plus 500 mg qd open-label ... Cited by 44 - Related articles - BL Direct - All 10 versions
- ►diabetesjournals.org P Raskin, L Klaff, J McGill, SA South, P Hollander, … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Final HbA 1c values were lower for repaglinide/metformin treatment than for
nateglinide/metformin (7.1 vs. 7.5%). Repaglinide/metformin therapy showed significantly greater
mean reductions of HbA 1c (−1.28 ... Cited by 47 - Related articles - BL Direct - All 7 versions
L Jovanovic, DR Hassman, B Gooch, R Jain, S … - Diabetes research and …, 2004 - Elsevier The efficacy and safety of combination therapy (repaglinide plus pioglitazone) was compared to
repaglinide or pioglitazone in 24-week treatment of type 2 diabetes. This randomized, multicenter,
open-label, parallel-group study ... Cited by 38 - Related articles - All 4 versions
P Raskin, J McGill, MF Saad, JM Cappleman, … - Diabetic …, 2004 - interscience.wiley.com Methods Enrolled patients (n = 252) were adults having Type 2 diabetes for at least 1 year, with HbA
1c values > 7.0% after previous monotherapy (sulphonylurea or metformin, ≥ 50% maximal dose).
Prior therapy was withdrawn for 2 ... Cited by 29 - Related articles - BL Direct - All 6 versions
FA Van de Laar, PL Lucassen, RP Akkermans … - Cochrane database of …, 2005 - ncbi.nlm.nih.gov BACKGROUND: Alpha-glucosidase inhibitors such as acarbose or miglitol, have the potential to improve
glycemic control in type 2 diabetes mellitus. The true value of these agents, especially in relation
to diabetes related mortality and ... Cited by 50 - Related articles - All 5 versions
- ►diabetesjournals.org NN Zammitt, BM Frier - Diabetes Care, 2005 - Am Diabetes Assoc The importance of strict glycemic control to limit the risk of diabetic vascular complications is
indisputable, but many barriers obstruct its attainment. Hypoglycemia is recognized to be a major
limitation in achieving good ... Cited by 89 - Related articles - All 6 versions
S Madsbad, B Kilhovd, I Lager, P Mustajoki, A … - Diabetic …, 2001 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets. In
this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the ... Cited by 30 - Related articles - BL Direct - All 6 versions
[CITATION] VA CSDM Group: VA Cooperative study on glycemic control and complications in …
